ACTG Publications

Cardiovascular disease risk factors in HIV-infected women after initiation of lopinavir/ritonavir- and nevirapine-based antiretroviral therapy in Sub-Saharan Africa: A5208 (OCTANE).Shaffer, Douglas ; Hughes, Michael D ; Sawe, Fredrick ; Bao, Yajing ; Moses, Agnes ; Hogg, Evelyn ; Lockman, Shahin ; Currier, Judith2014 Jun 1J Acquir Immune Defic Syndr266
Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention.Podany, Anthony T ; Bao, Yajing ; Swindells, Susan ; Chaisson, Richard E ; Andersen, Janet W ; Mwelase, Thando ; Supparatpinyo, Khuanchai ; Mohapi, Lerato ; Gupta, Amita ; Benson, Constance A ; Kim, Peter ; Fletcher, Courtney V ; AIDS Clinical Trials Group A5279 Study Team2015 Oct 15Clin Infect Dis861
Changes in HIV-1 subtypes B and C genital tract RNA in women and men after initiation of antiretroviral therapy.Fiscus, Susan A ; Cu-Uvin, Susan ; Eshete, Abel Tilahun ; Hughes, Michael D ; Bao, Yajing ; Hosseinipour, Mina ; Grinsztejn, Beatriz ; Badal-Faesen, Sharlaa ; Dragavon, Joan ; Coombs, Robert W ; Braun, Ken ; Moran, Laura ; Hakim, James ; Flanigan, Timothy ; Kumarasamy, N ; Campbell, Thomas B ; A5185s Team2013 JulClin Infect Dis257
Low-frequency nevirapine (NVP)-resistant HIV-1 variants are not associated with failure of antiretroviral therapy in women without prior exposure to single-dose NVP.Boltz, Valerie F ; Bao, Yajing ; Lockman, Shahin ; Halvas, Elias K ; Kearney, Mary F ; McIntyre, James A ; Schooley, Robert T ; Hughes, Michael D ; Coffin, John M ; Mellors, John W ; OCTANE/A5208 Team2014 Mar 1J Infect Dis5209